Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome

Authors: Xuguang Hu, Man Wang, Weijian Bei, Zongyu Han, Jiao Guo

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Insulin resistance plays an important role in the development of metabolic syndrome (MS). Fu Fang Zhen Zhu Tiao Zhi formula (FTZ), a Chinese medicinal decoction, has been used to relieve hyperlipidemia, atherosclerosis and other symptoms associated with metabolic disorders in the clinic.

Methods

To evaluate the effect of FTZ on insulin resistance, HepG2 cells were induced with high insulin as a model of insulin resistance and treated with FTZ at one of three dosages. Next, the levels of glucose content, insulin receptor substrate1 (IRS1) protein expression and phosphatidylinositol 3-kinase (PI3K) subunit p85 mRNA expression were measured. Alternatively, MS was induced in rats via gavage feeding of a high-fat diet for four consecutive weeks followed by administration of FTZ for eight consecutive weeks. Body weight and the plasma levels of lipids, insulin and glucose were evaluated. Finally, the expression of PI3K p85 mRNA in adipose tissue of rats was measured.

Results

Our results revealed that FTZ attenuated glucose content and up-regulated the expression of PI3K p85 mRNA and IRS1 protein in insulin-resistant HepG2 cells in vitro. Moreover, FTZ reduced body weight and the plasma concentrations of triacylglycerol, cholesterol, fasting glucose and insulin in insulin resistant MS rats. FTZ also elevated the expression of PI3K p85 mRNA in the adipose tissues of MS rats.

Conclusion

FTZ attenuated MS symptoms by decreasing the plasma levels of glucose and lipids. The underlying mechanism was attenuation of the reduced expression of PI3K p85 mRNA and IRS1 protein in both insulin-resistant HepG2 cells and MS rats.
Appendix
Available only for authorised users
Literature
1.
go back to reference Reaven GM: Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1607. 10.2337/diab.37.12.1595.CrossRefPubMed Reaven GM: Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1607. 10.2337/diab.37.12.1595.CrossRefPubMed
2.
go back to reference Zimmet PZ, McCarty DJ: The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications. 1997, 11: 60-68. 10.1016/S1056-8727(96)00090-6.CrossRefPubMed Zimmet PZ, McCarty DJ: The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications. 1997, 11: 60-68. 10.1016/S1056-8727(96)00090-6.CrossRefPubMed
3.
go back to reference Guo J: A drug for the treatment of hyperlipidemia[P]. 2004, China, 0410051250.4 Guo J: A drug for the treatment of hyperlipidemia[P]. 2004, China, 0410051250.4
4.
go back to reference Cao Y, Bei W, Hu Y, Cao L, Huang L, Wang L, Luo D, Chen Y, Yao X, He W, Liu X, Guo J: Hypocholesterolemia of Rhizoma Coptidis alkaloids is related to the bile acid by up-regulated CYP7A1 in hyperlipidemic rats. Phytomedicine. 2012, 19: 686-692. 10.1016/j.phymed.2012.03.011.CrossRefPubMed Cao Y, Bei W, Hu Y, Cao L, Huang L, Wang L, Luo D, Chen Y, Yao X, He W, Liu X, Guo J: Hypocholesterolemia of Rhizoma Coptidis alkaloids is related to the bile acid by up-regulated CYP7A1 in hyperlipidemic rats. Phytomedicine. 2012, 19: 686-692. 10.1016/j.phymed.2012.03.011.CrossRefPubMed
5.
go back to reference Tong G, Jiao G, Wei H: The clinical observation of Fufang Zhenshu Tiaozhi on hyperlipemia. Journal of Shandong University of TCM. 2006, 30: 204-206. Tong G, Jiao G, Wei H: The clinical observation of Fufang Zhenshu Tiaozhi on hyperlipemia. Journal of Shandong University of TCM. 2006, 30: 204-206.
6.
go back to reference Guo J, Bei WJ, Tang CP: The effect of Fufang Zhenshu Tiaozhi extract on hepatic lipase in diet-induced hyperlipidemic rats. Zhong Yao Cai. 2009, 32: 582-585. Guo J, Bei WJ, Tang CP: The effect of Fufang Zhenshu Tiaozhi extract on hepatic lipase in diet-induced hyperlipidemic rats. Zhong Yao Cai. 2009, 32: 582-585.
7.
go back to reference Tong G, Jiao G, Yingyu L: The effect of Fufang Zhenshu Tiaozhi on the viscosity of plasma and whole blood in hyperlipidemic patients. Journal of Practical traditional Chinese medicine. 2006, 22 (10): 608-609. Tong G, Jiao G, Yingyu L: The effect of Fufang Zhenshu Tiaozhi on the viscosity of plasma and whole blood in hyperlipidemic patients. Journal of Practical traditional Chinese medicine. 2006, 22 (10): 608-609.
8.
go back to reference Wu HY, Bei WJ, Guo J: Chinese herbal medicine for the treatment of dyslipidemia. J Geriatr Cardiol. 2009, 6: 119-125. Wu HY, Bei WJ, Guo J: Chinese herbal medicine for the treatment of dyslipidemia. J Geriatr Cardiol. 2009, 6: 119-125.
9.
go back to reference Guo J, Bei WJ, Hu YM, Tang CP, He W, Liu XB, Huang LH, Cao Y, Hu XG, Zhong XL, Cao L: A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats. J Ethnopharmacol. 2011, 135: 299-307. 10.1016/j.jep.2011.03.012.CrossRefPubMed Guo J, Bei WJ, Hu YM, Tang CP, He W, Liu XB, Huang LH, Cao Y, Hu XG, Zhong XL, Cao L: A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats. J Ethnopharmacol. 2011, 135: 299-307. 10.1016/j.jep.2011.03.012.CrossRefPubMed
10.
go back to reference Xunlong Z, Jiao G, Laiyou W: Analysis of the constituents of the prototype and metabolite constituents in rat serum after oral administration of Fu Fang Zhen Zhu Tiao Zhi capsule by UPLC-Q-TOF MS/MS. Chromatographia. 2012, 75: 111-129. 10.1007/s10337-011-2164-6.CrossRef Xunlong Z, Jiao G, Laiyou W: Analysis of the constituents of the prototype and metabolite constituents in rat serum after oral administration of Fu Fang Zhen Zhu Tiao Zhi capsule by UPLC-Q-TOF MS/MS. Chromatographia. 2012, 75: 111-129. 10.1007/s10337-011-2164-6.CrossRef
11.
go back to reference Zhou L, Meng Q, Qian T, Yang Z: Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells. J Nat Med. 2011, 65: 50-56. 10.1007/s11418-010-0456-z.CrossRefPubMed Zhou L, Meng Q, Qian T, Yang Z: Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells. J Nat Med. 2011, 65: 50-56. 10.1007/s11418-010-0456-z.CrossRefPubMed
12.
go back to reference Zhang WY: Scopoletin improves insulin resistance by scopoletin in high-glucose-induced, insulin-resistant HepG2 cells. Horm Metab Res. 2010, 42: 930-935. 10.1055/s-0030-1265219.CrossRefPubMed Zhang WY: Scopoletin improves insulin resistance by scopoletin in high-glucose-induced, insulin-resistant HepG2 cells. Horm Metab Res. 2010, 42: 930-935. 10.1055/s-0030-1265219.CrossRefPubMed
13.
go back to reference Renstrfm F: Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. Metabolism Clinical and Experimental. 2007, 56: 190-198. 10.1016/j.metabol.2006.09.012.CrossRef Renstrfm F: Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. Metabolism Clinical and Experimental. 2007, 56: 190-198. 10.1016/j.metabol.2006.09.012.CrossRef
14.
go back to reference Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER: Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010, 47 (2): 165-169. 10.1590/S0004-28032010000200009.CrossRefPubMed Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER: Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010, 47 (2): 165-169. 10.1590/S0004-28032010000200009.CrossRefPubMed
15.
go back to reference Nakamaru K, Matsumoto K, Taguchi T, Suefuji M, Murata Y, Igata M, Kawashima J, Kondo T, Motoshima H, Tsuruzoe K, Miyamura N, Toyonaga T, Araki E, AICAR: An activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells. Biochem Biophys Res Commun. 2005, 328: 449-454. 10.1016/j.bbrc.2005.01.004.CrossRefPubMed Nakamaru K, Matsumoto K, Taguchi T, Suefuji M, Murata Y, Igata M, Kawashima J, Kondo T, Motoshima H, Tsuruzoe K, Miyamura N, Toyonaga T, Araki E, AICAR: An activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells. Biochem Biophys Res Commun. 2005, 328: 449-454. 10.1016/j.bbrc.2005.01.004.CrossRefPubMed
16.
go back to reference Woods A, Zzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D: Characterization of the role of AMP-activated protein kinase in the regulation of glucose activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol. 2000, 20: 6704-6711. 10.1128/MCB.20.18.6704-6711.2000.PubMedCentralCrossRefPubMed Woods A, Zzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D: Characterization of the role of AMP-activated protein kinase in the regulation of glucose activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol. 2000, 20: 6704-6711. 10.1128/MCB.20.18.6704-6711.2000.PubMedCentralCrossRefPubMed
17.
go back to reference Zhou L, Sell H, Eckardt K, Yang Z, Eckel J: Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes. FEBSLett. 2007, 581: 4303-4308. 10.1016/j.febslet.2007.07.076.CrossRef Zhou L, Sell H, Eckardt K, Yang Z, Eckel J: Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes. FEBSLett. 2007, 581: 4303-4308. 10.1016/j.febslet.2007.07.076.CrossRef
18.
go back to reference Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA: AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem. 2004, 279: 47898-47905. 10.1074/jbc.M408149200.CrossRefPubMed Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA: AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem. 2004, 279: 47898-47905. 10.1074/jbc.M408149200.CrossRefPubMed
20.
go back to reference Carvalho E, Rondinone C, Smith U: Insulin resistance in fat cells from obese Zucker rats-evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4. Mol Cell Biochem. 2000, 206: 7-16. 10.1023/A:1007009723616.CrossRefPubMed Carvalho E, Rondinone C, Smith U: Insulin resistance in fat cells from obese Zucker rats-evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4. Mol Cell Biochem. 2000, 206: 7-16. 10.1023/A:1007009723616.CrossRefPubMed
21.
go back to reference Stanhope KL, Havel PJ: Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol. 2008, 19: 16-24. 10.1097/MOL.0b013e3282f2b24a.PubMedCentralCrossRefPubMed Stanhope KL, Havel PJ: Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol. 2008, 19: 16-24. 10.1097/MOL.0b013e3282f2b24a.PubMedCentralCrossRefPubMed
22.
go back to reference Liu I-M, Tzeng T-F, Liou S-S: A Chinese herbal decoction, Dang Gui Bu Xue Tang, prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates insulin resistance induced by a high-fructose diet in rats. Evid Based Complement Alternat Med. 2011, 2011: 1-11. Liu I-M, Tzeng T-F, Liou S-S: A Chinese herbal decoction, Dang Gui Bu Xue Tang, prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates insulin resistance induced by a high-fructose diet in rats. Evid Based Complement Alternat Med. 2011, 2011: 1-11.
23.
go back to reference Wang X, Liu R, Zhang W, Zhang X, Liao N, Wang Z, Li W, Qin X, Hai C: Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. Mol Cell Endocrinol. 2013, 376: 70-80. 10.1016/j.mce.2013.06.014.CrossRefPubMed Wang X, Liu R, Zhang W, Zhang X, Liao N, Wang Z, Li W, Qin X, Hai C: Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. Mol Cell Endocrinol. 2013, 376: 70-80. 10.1016/j.mce.2013.06.014.CrossRefPubMed
24.
go back to reference Yang G, Min-fei Y, Ya-ping S, Hui-min J, Xiao-juan Y, Yin-jing Y, Hai-long Z: Ginsenoside Re reduces insulin resistance through activation of PPAR-γ pathway and inhibition of TNF-α production. J Ethnopharmacol. 2013, 147: 509-516. 10.1016/j.jep.2013.03.057.CrossRefPubMed Yang G, Min-fei Y, Ya-ping S, Hui-min J, Xiao-juan Y, Yin-jing Y, Hai-long Z: Ginsenoside Re reduces insulin resistance through activation of PPAR-γ pathway and inhibition of TNF-α production. J Ethnopharmacol. 2013, 147: 509-516. 10.1016/j.jep.2013.03.057.CrossRefPubMed
25.
go back to reference Li-Zhong L, Stanley C.K C, Lin-Lin L, Stanley K.S H, Hong-Xi X, Julian C.N C, Peter C.Y T: Berberine modulates insulin signaling transduction in insulin-resistant cells. Mol Cell Endocrinol. 2010, 317: 148-153. 10.1016/j.mce.2009.12.027.CrossRef Li-Zhong L, Stanley C.K C, Lin-Lin L, Stanley K.S H, Hong-Xi X, Julian C.N C, Peter C.Y T: Berberine modulates insulin signaling transduction in insulin-resistant cells. Mol Cell Endocrinol. 2010, 317: 148-153. 10.1016/j.mce.2009.12.027.CrossRef
Metadata
Title
The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome
Authors
Xuguang Hu
Man Wang
Weijian Bei
Zongyu Han
Jiao Guo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-47

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.